Research Analysts Issue Forecasts for VRDN Q1 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at B. Riley issued their Q1 2025 earnings per share estimates for Viridian Therapeutics in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will earn ($1.09) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. B. Riley also issued estimates for Viridian Therapeutics’ Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($4.74) EPS, FY2026 earnings at ($4.95) EPS, FY2027 earnings at ($3.61) EPS and FY2028 earnings at ($2.64) EPS.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Several other research firms also recently weighed in on VRDN. Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Royal Bank of Canada raised their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, TD Cowen initiated coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $15.23 on Wednesday. The company has a market capitalization of $1.21 billion, a P/E ratio of -3.53 and a beta of 1.32. The business’s 50 day moving average is $18.02 and its two-hundred day moving average is $19.70. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 12-month low of $11.40 and a 12-month high of $27.20.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRDN. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at $26,000. Foresite Capital Management VI LLC acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at $38,000. AlphaQuest LLC grew its stake in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Viridian Therapeutics in the third quarter valued at $149,000. Finally, Summit Investment Advisors Inc. boosted its holdings in Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after purchasing an additional 1,516 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.